Constrained Spirocyclic Compounds for CGRP Receptor Antagonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders involving CGRP, such as migraine and cluster headache, lack effective antagonists that can specifically target CGRP receptors to prevent or alleviate symptoms.
Innovation Solution
Development of compounds that act as antagonists for CGRP receptors, specifically designed to bind to and inhibit the action of CGRP, thereby reducing vasodilation and neuronal sensitization associated with these disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for migraine and cluster headache, then current therapeutic options are available, but effective antagonists that can specifically target CGRP receptors are lacking
Solution Approach 1:
The patent modifies molecular parameters of the compound structure (formula I) to optimize CGRP receptor binding affinity and selectivity. By adjusting substituents at specific positions (R1-R6, R7-R11, R12-R16) and stereochemical configurations, the compounds achieve high reliability in CGRP receptor targeting while maintaining specificity through precise molecular geometry and interaction patterns.
Solution Approach 2:
The invention employs composite molecular structures combining multiple functional moieties within a single molecule. The compounds integrate hydrophobic regions, hydrogen bonding groups, and electrostatic interaction sites to create a unified antagonist structure that simultaneously achieves reliable receptor binding and specific CGRP targeting through synergistic molecular interactions.
2Reliability
If CGRP receptor antagonists are developed to prevent migraine and cluster headache, then targeted therapeutic effect is achieved, but compound complexity increases
Solution Approach 1:
The patent divides the molecular structure into distinct functional segments (formula I with defined regions A-F). Each segment serves a specific purpose: certain substituents handle receptor binding, others manage selectivity, and additional groups optimize pharmacokinetic properties. This segmentation allows systematic design to achieve therapeutic reliability while managing overall structural complexity through modular assembly.
Solution Approach 2:
The invention applies local quality by optimizing specific regions of the molecule for particular functions. Different substituents are placed at specific positions (e.g., R1-R4 region vs. R7-R16 region) to create localized functional zones - some areas prioritize binding affinity while others emphasize selectivity or metabolic stability, thereby achieving therapeutic effectiveness without uniform complexity throughout the entire structure.
3Reliability
If existing CGRP antagonist options are used, then some therapeutic effect is achieved, but lack of specific targeting reduces treatment precision
Solution Approach 1:
The patent replaces non-specific binding mechanisms with precise molecular recognition systems. The compounds utilize specific molecular interactions including hydrogen bonds, salt bridges, and van der Waals forces at defined interaction sites to achieve precise CGRP receptor targeting. This substitution of generic binding with specific molecular recognition mechanisms provides both reliable therapeutic response and precise receptor targeting.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively prevent or treat conditions like migraine and cluster headache by blocking CGRP receptor activity, providing a targeted therapeutic approach to manage symptoms and prevent attacks.
Implementation Method 1
compounds that are useful as ligands for CGRP receptors, in particular antagonists for CGRP receptors
Data Source
AI summary
Compounds of formula I:(wherein variables A1, A2, A3, G1, G2, G3, J, m, n, p, R1, R2, R3, R4 and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.